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Background: CD44 is considered as ‘a’ metastasis associated gene, despite the fact that it is an umbrella term for
a group of molecules produced from a single gene by alternative splicing. However, little consideration is given
to the above in the literature of colorectal carcinomas as well as other tumour types, leading to confusion and
contradictory results about its possible role in tumour progression.
Methods: We compared the CD44 alternative splice pattern (ASP) of three genetically different human colorectal
cancer cell lines (HT25, HT29, HCT116) using a series of PCR reactions and next- generation sequencing method,
as well as identified a colorectal adenocarcinoma specific CD44 ASP. This ASP was further investigated in terms of
its qualitative and quantitative stability in our experimental iso- and xenograft mouse models for colorectal cancer
progression. A complex preclinical experimental set-up was established to separately test the different steps of tumour
progression and the role of tumour microenvironment, respectively, focusing on the role of ‘CD44’ in this process.
Results: We managed to present a colorectal cancer-specific CD44 ASP, which remained unchanged from cell
lines throughout primary tumour formation and metastatic progression. Furthermore, we report a unique roster of all
expressed CD44 variant isoforms characteristic to colorectal cancer. Finally, on quantitative assessment of the variable
exons v3 and v6, higher co-expression levels were found to be characteristic to metastatically potent tumour cells.
Conclusion: Particular CD44 variant isoforms seem to act as “metastasis genes” via tumour microenvironment-driven
shifts in v3 and v6 expressions. However, this function may just affect a minority of tumour subclones. This fact and
the huge potential number of different CD44 splice variants that can contain v3 and v6 domains can explain
incoherence of clinical studies regarding functional asessment of CD44 variants, as well as diminish the chances of
using CD44 variants for predictive purpose.
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In developed countries, colorectal cancer (CRC), or ra-
ther its progression to metastatic disease, accounts for
25% of tumour deaths [1]. Characterising the metastases
associated processes is therefore of crucial importance
for identifying ways of earlier and more sensitive diagno-
sis, more defined prognosis, and possibly in the selection
of patients for targeted therapies.* Correspondence: bankybalazs@yahoo.com
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reproduction in any medium, provided the orA variety of genes have been described and extensively
investigated in the literature as key candidates in the
tumorigenesis and progression of colorectal carcinoma,
including APC, p53, K-ras, BRAF, DCC, MSH, EGFR,
SFK, TGFR2, SMAD4, etc. [2-5].
Each individual step of the metastatic cascade is
the result of complex molecular interactions, regulated
by several already identified and/or unidentified genes
[6]. One of the candidates of key importance has
been CD44. In fact, it is one of the most investig-
ated molecules in the metastatic process of several
malignancies [7-13], among them that of colorectal
cancer [14-16].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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receptor [17]. The role of CD44 was later proven in fetal
arteriogenesis [18], as well.
Furthermore, expression and function of various isoforms
of CD44 were detected in chronic inflammatory diseases
(rheumatoid arthritis, ulcerative colitis, resolution of lung
inflammations, etc.) [19-21].
A number of studies demonstrated the expression of
CD44s (standard version) on most tissue types of epithe-
lial origin (stomach mucous membrane, small intestinal
mucosa, prostate, ductal epithelium of breast, skin, hair
follicules, transitional cell membrane of utgenital tract)
[22-26]. Regarding colonic mucosa, immunohistochem-
ical examinations demonstrated that CD44s (identified
with antibody against the standard region of the mol-
ecule) is located at the level of basal crypts, similar to
the “intestinal stem cells” of the small intestine sitting
between Paneth-cells [27-29]. This means that prolifera-
tive cells of colonic mucosa, as well as cells in the basal
segment of differentiation zone are able to provide
CD44s expression, while differentiated mucosal cells
don’t show membrane positivity on immunostaining any
more [30]. This fact gains special importance when con-
sidering the change of ‘CD44’ expression characteristics
from the normal, the dysplastic and the malignant colo-
rectal tissues [31].
Additionally, and probably not independently form the
above mentioned findings, recent studies demonstrated
‘CD44’ as a potential tumour stem cell marker (in colo-
rectal, gastric and pancreatic adenocarcinoma, as well as
breast cancer and other cancers) [32-39].
With the presence of CD44 protein in so many tissues,
consideration has to be given to its physiological and
pathological functions.
‘CD44’ has a variety of biological functions such as
cell-cell, cell-ECM interactions, tumour cell migration
[40,41] or even chemoresistance [16,41-50]. This multi-
tude of representations and functions is less surpris-
ing when considering that through its 9 variable exons
(v2-v10), hundreds of different isoforms can be tran-
scribed and translated from the single CD44 gene result-
ing in a mixture of glycoproteins with potentially different
functions [51-53]. Talking about ’CD44’ and studying its
’over expression’ therefore is rather debatable and not as
straight-forward as it was previously thought. A basic
understanding and consideration of alternative splicing
should be warranted when dealing with this versatile
gene. For the same reason, when using probes (i.e. pri-
mers or antibodies) against the standard region of CD44
(CD44s), one will detect a mixture of isoforms as they all
share the same standard region [54,55].
Determining the role of ’CD44’ is further complicated
by the difficulties to identify all the isoforms potentially
characterizing certain cell or tissue types. The trend is tofocus on the expression of a single variable exon, which,
of course, will only show the summation of isoforms
containing the exon in question. However, these iso-
forms might only share a single variable exon, therefore
they can be of different functions. In addition, several
other CD44 variant isoforms can be present within the
same cell, adding further functions to ’CD44’ [56-59].
Furthermore, different cells of a tumour can express
various, possibly different sets of CD44 isoforms. As
most of our tests examine a group of cells from the
tissue at the same time, the results are summated, failing
to represent the cell-to-cell differences in details [6]. In
colorectal carcinoma the most studied variant exons /
protein domains are v3 and v6.
CD44v3 is the heparane-sulphate proteoglycane domain
of CD44, however, the v3-containing isoforms of CD44
have hyaluronate binding potential and may contain a
chondroitin-sulphate proteoglycan domain as well. Con-
sequently, CD44v3 can bind different heparin-binding
growth factors (GF), such as HBEGF, VEGF, HGF, βFGF,
KGF and amphiregulin [60,61].
CD44v6 functions as receptor of HGF/SF cooperating
with c-met [61,62], regulating EMT and taking part in
the positive feedback loop of K-ras activation driving
both Ras signal transduction pathway and CD44-splicing
machinery [3,63,64]. Additionally, this is the domain
most frequently found to be associated with metastatic
phenotype in the literature [65].
Unsurprisingly, the studies of detecting ‘v3’ and ‘v6’
under different experimental and clinical settings do not
lead to coherent results, and can even be contradictory.
This also can be observed in the literature regarding
colorectal cancer [14,66-71].
Recently, characteristic CD44 isoform patterns of
different normal tissue types have been described in the
literature [24-26,72,73] and our earlier studies described
CD44 isoform patterns characteristic of different tumour
types, respectively (data publication in progress, Rásó-
Barnett et al.). Most of the literature agrees that ‘CD44’
plays an important role during tumour progression
based on ‘overexpression’ of specific variant regions con-
taining isoforms at mRNA and/or protein level. How-
ever, no data is available concerning the pattern of CD44
isoforms and its modulation during tumour progression.
Our previous study on CD44 alternative splice patterns
showed no qualitative change of the melanoma specific
‘CD44-fingerprint’, while the expression level of all iso-
forms uniformly increased during the metastatic process
(data publication in progress, Rásó-Barnett et al.).
The aim of our research was to find answers to the
following two questions: (1) Is there a colorectal car-
cinoma specific CD44 isoform expression combination
like to one identified in human melanoma? If there
is such pattern, is it qualitatively / quantitatively stable
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of the incoherent quantitative results on the expres-
sion of the most investigated v3 and v6 variable exons /
protein domains?
To answer the first question, we designed primer pairs
covering the entire variable region (primers A-B, see
Methods) for our quantitative and qualitative PCR reac-
tions. The expressed, i.e. transcribed CD44 isoforms
were identified using direct sequencing and next-
generation sequencing.
Due to the large number of potential isoforms, we
used a series a PCR reactions to create the CD44 finger-
print, a simple, easy to handle representation of the
expressed CD44 isoforms. We used this fingerprint to
track the changes of CD44 expression during tumour
progression [41,55,74-76].
To answer our second question, we designed a com-
plex experimental animal model to examine the func-
tional role CD44v3 and CD44v6 containing isoforms
play in metastasis formation. The main question was
whether or not there is a change in the expression of
these variable exons that could be associated to the
metastatic process of human colorectal carcinoma. We
implanted the same colorectal cancer cell population
orthotopically to form real metastases in liver, as well as
heterotopically. We performed two types of heterotopic
implantation: the first involved subcutaneous implant-
ation into permissive and non-permissive hosts, the sec-
ond was direct implantation into the spleen so that the
implanted cells could directly colonize the liver. The latter
method created a new type of secondary tumour, which
albeit is in the same localization as the liver metastases of
the true metastatis model, has not been through the
metastatic cascade. This experimental setup allowed to
functionally differenciate between phases of metastatic
process and host related changes, regarding the expres-
sion activity of the examined variable CD44 exons.
Results
Colorectal adenocarcinoma (CRC) specific CD44
alternative splice pattern (ASP)
Human colorectal cell lines (HT25, HT29, HCT116)
could be characterized by the dominance of five bands
on agarose gel electrophoretograms (ELFO) when exam-
ining the variant region of CD44 with a primer pair test-
ing and overlapping the entire variant region (Primer A
– Primer B) Figure 1, Figure 2B. This PCR reaction
would theoreticaly amplify each transcribed CD44 vari-
ant isoform. In three of the five bands (372 bp, 564 bp,
768 bp) we identified a particular CD44 isoform by dir-
ect sequencing. Even these bands, as well as those bands
which were not definitely identified by direct sequen-
cing, potentially ‘hide’ more, different isoforms. None of
the dominant PCR producs that were identified by directsequencing represented v3 or v6 containing isoforms.
Next-generation sequencing (NGS) performing allele
specific high performance sequencing managed to iden-
tify further isoforms including some of those which
contain v3/v6 exon products. This method managed to
differentiate more isoforms hidden behind the same
ELFO bands. Furthermore, eight more isoforms with
very low expression activities were identified by this sen-
sitive method. These isoforms do not appear on the
qualitative picture of ELFO. (Surprisingly, NGS provided
evidence to the fact that CD44 isoform without any vari-
ant exons (CD44v0) does exist, in spite of the widely
accepted theory that v1 variant exon is constitutively
expressed) Figure 1.
Additionally, we identified a number of definitely
expressed CD44 isoforms by four further PCR sets per-
formed with primer pairs directly designed onto exons
v3 and v6 (Primer pairs A-D, A-E, C-B, C-E) Figure 1,
Figure 2A. Primers designed for particular exons (e.g. v3
or v6) gave evidence of that exon being transcribed, as a
minimal premise of amplification on PCR. Some of these
isoforms did not appear among the products of the reac-
tion ‘A-B’, either for some quantitative or particular PCR
reaction technical reasons. Precise knowledge of exon
lengths enabled us to calculate the expression of further
isoforms according to product sizes in addition to the
ones detected by direct sequencing of PCR products.
These two methods provided a rich roster of definite
and estimated CD44 isoforms which are represented by
being isoforms of very similar size.
This way we identified CD44 isoforms expressed in
CRC cell lines from a qualitative picture derived from
five-primer-pair PCR series covering the entire length of
the variable region of CD44 with overlapping sequences.
By running the PCR products of the five different primer
pair reactions on agarose gel always in the same order, a
colorectal cancer specific alternative splice pattern (ASP)
could be described for all three human colorectal cell
lines (HT29, HCT116 and HT25) Figure 2B.
Colorectal specificity of this CD44-fingerprint is
detailed and proven elsewhere (publication in progress,
Rásó-Barnett et al.), here we just demonstrate a few
samples of CD44 fingerprints of other tumour types, i.e.
MCF7 (breast cancer), HT199 (melanoma), A431 (vulvar
epidermoid carcinoma), and K562 (myelogenous leu-
kemia) respectively.
After all, there were 26 different CD44 isoforms identi-
fied in the qualitative CD44 fingerprint of colorectal can-
cer, 24 of which were proven by sequencing and only
two remained ‘estimated/calculated’ isoforms Figure 1.
However further isoforms can also be present, only
hidden behind ‘truncated’ CD44 isoforms sharing the
same truncated part of the whole molecule (i.e. Isoform
14–26 on Figure 1.).
Figure 1 Expressed CD44 isoforms in colorectal cancer. Agarose gel electrophoretogram of PCRs with primer combination A-B, A-D, A-E, C-B,
C-E on human CRC cell line HT29. (1. 100bp DNA ladder; 2. CD44 expression pattern of HT29 suspension). Primer design shown on Figure 2A.
Expressed CD44 isoforms in colorectal cancer were detected. PCR with A-B primer pair can theoretically provide all expresed isoforms, but for
the reason of sensitivity limitations of PCR technique only five main bands were detected. PCRs with the other four primer pairs could reveal
expressed (quantitatively inferior) isoforms containing v3 and v6 exon products.Some of the bands could be identified as distinct isoform products
(proven by direct sequencing), others covered more, similar length isoforms identified by allele-specific next-generation sequencing or estimated by
length calculation of the products. Estimated/calculated isoforms are shown in Italic, red letters. Twenty-six CD44 isoforms could be differentiated this
way, some of them are just truncated, so that may in fact cover several isoforms sharing the same common variant exons.
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colorectal CD44 ‘fingerprint’
Comparison of tumours growing in vitro and in vivo
CD44 pattern of our samples from the xenotransplant-
ation model has proven that the pattern is preserved
in vivo the same way it was seen in vitro. ASP of CD44was found to be highly similar of HT29 cells cultured
in vitro as compared to orthotopic primary (colon) or
heterotopic primary (spleen, subcutaneously in adult and
newborn mice) Figure 2D,E. HT25 and HCT116 cell
lines were found to behave the same conservative way,
(data not shown).
Figure 2 Agarose gel electrophoretograms demonstrating CD44 isoform expression pattern of human CRC (colorectal specific „CD44
fingerprint”). A. Primers designed on CD44 (Primer assembly: 1. A-B; 2. A-D; 3. A-E; 4. C-B; 5. C-E). B. ’CD44 fingerprint’ of colorectal cancer
suspensions (HT29, HCT116 and HT25) in vitro A highly similar pattern of the expressed CD44 isoforms can be recognised. C. CD44 fingerprint
of different human malignant cell line types: MCF7 human breast cancer cell line, HT199 human malignant melanoma cell line, A431 human
vulvar carcinoma cell line and K562 human myelogenois leukemia cell line, respectively. D. CD44 fingerprint of HT29 colorectal cancer xenografts
in orthotopic implantation model and liver colonization model. Both primary colon tumours and their liver metastases, as well as spleen
primary tumours (heterotopic implantation of colon tumour suspension) and the developed liver secondaries swow the same CD44 isoform
expression pattern. E. CD44 fingerprint of HCT116 xenografts in spontaneous pulmonary metastasis model of subcutaneous tumour implantation:
subcutaneous primary tumours in adult and in newborn, as well as pulmonary metastases in newborn scid mice expressed the same, colorectal
carcinoma specific CD44 fingerprint on serial PCR and agarose gel ELFO. (Adult mice after subcuticular tumour implantation never developed
pulmonary metastases).
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(ASP) during the metastatic process of the tumours
To determine whether the expression pattern changes
during the metastatic process in our xenograft system,
we implanted HT29 cell suspension into spleen and
orthotopically into large bowel, coecal wall. We then
compared the CD44 pattern of the primary tumour and
the liver metastasis/colony of the same animal in both
models. The pattern was found to be unchanged
Figure 2D. Similar, unchanged expression patterns were
detected in the other two tumour types, HT25 and
HCT116, respectively (data not shown).
In the case of HT29, the heterotopically (subcutane-
ous) implanted primary tumour showed the exact same
pattern as the cell suspension in both the metastatic
(newborn) and non-metastatic (adult) host. In metastatic
cases (in each newborn animal) pulmonary metastases
gave the same ASP, as well Figure 2E. The number
of implanted animals in each arm of the model was
three, the qualitative expression pttern was overally
homogenous. (A total number of 40 animals were trans-
planted, 28 of them developed metastases, and we used
3–3 animals to check the CD44 fingerprint.)
Quantitative change of certain exons (v3/v6) of the CD44
variable region during tumour progression of colorectal
cancer in mice
Mouse C26 isograft system
CD44v3 and CD44v6 expressions of orthotopic (coonic
wall) and heterotopic (splenic implantation) primary
C26 tumours (four mice in each group), as well as spon-
taneous liver metastases and liver colonies (from splenic
implantation) were compared using real-time PCR
Figure 3A. Data indicate that while the expression level
of both variable exons were more than one magnitude
larger in the liver metastases compared to that of the
primary tumour in the orthotopic implantation model
(significant differences both on v3 and v6 expression),
no significant alteration was detected between the spleen
primary and the liver colony. Furthermore, it is remark-
able that primary tumours of both systems showed
similar expression levels.
Human colon cancer xenografts
All three implanted human colon cancer lines (HT29,
HT25, HCT116) possessed similar metastatic potential
in both systems, showing a 50–65 % metastatic rate.
Real time PCR measurement using CD44v3 and
CD44v6 exon specific primers showed three different
ways of behaviour in the three colorectal cell types.
In representative samples we compared the relative
CD44v3 and CD44v6 levels of the primary tumours and
liver metastases or liver colonies in both systems, simi-
larly to the isograft experiments Figure 3B.In case of HT29, identically to C26, we detected sig-
nificantly elevated expression levels in liver metastases
after orthotopic implantation compared to the primary
tumour of the colonic wall, while both variable exons
were expressed at the same level in both the primary
splenic tumour and the liver colony of the spleen-liver
system. It is also interesting that primary tumours from
both localisations showed similar expression levels.
HT25 behaves opposite to Balb/C-C26 isograft system.
Primary tumours and metastases both showed identical
expression levels in the orthotopic system.In the case of
HCT116, the primary tumours provided extremely high
CD44v3/v6 expression levels. Liver metastases showed a
magnitude lower expression level. Therefore, the third
cell line represents a completely different, third pattern
of behavior Figure 4A.
Spontaneous lung metastasis xenograft model from
subcutaneous implantation
The same three, genetically different human colorectal
cell suspensions (HT25, HT29, HCT116) were implanted
into lumbar subcutaneous localization of three-three
adult and newborn scid mice. No metastases were
formed in the adult animals, while each newborn devel-
oped distant lung metastases. CD44v3 and CD44v6
expression levels of non-metastatic adult and metastatic
newborn primary tumours were measured. The results
from the three examined human xenografts are sum-
marised on Figure 3C.
The difference in v3 and v6 variant expression level
between the metastatic newborn and non-metastatic
adult primary tumours is clearly demonstrated. The ten-
dency is uniform across all three CRC tumours in this
model, showing 2–3 fold higher v3 and v6 expression
levels in the newborn than in adult primary tumours,
however the difference with three animals in each arm
could just reach the level of significance in the case of
HCT116 colorectal tumour type.
Discussion
Despite hundreds of published studies on CD44 within
the last two decades, noconsensus opinion has been
reached as of today apart from that it plays some role in
tumour progression [69,76]. One of the possible expla-
nations is that from microarrays to immunohistochemis-
try, the overwhelming majority of studies fail to take
into consideration that ‘CD44’ is a collection of isoforms
generated via alternative splicing of its nine variable
exons. Probes, primers and antibodies against the stand-
ard region will recognise a pool of different isoforms as
they all share the same standard region, and not the
isoform itself, which is functionally active and involved
in the metastatic process. A good example of this is
colorectal adenocarcinoma, where the cells of origin, i.e.
Figure 3 CD44v3 and CD44v6 expression activity in mouse isograft CRC metastatic and liver colonisation system. A. Semi-quantitative
CD44v3 and v6 gene expression activity of primary and secondary C26 colon carcinoma isograft tumours implanted orthotopically (colonic) and
intrasplenic (liver colonisation model) into Balb/C mice.While in „proper” metastatic system (orthotopic implantation) liver metastases expressed
CD44v3/v6 at significantly higher level than colon primaries, in colonisation model liver colonies showed similar expression profile to spleen
primaries. B. CD44 v3 and v6 gene expression activity of primary and secondary HT29 human colon carcinoma xenografts in orthotopic and
intrasplenic implantation models to scid mice. Selection of CD44v3/v6 high subclone at primary site can be suspected, as liver metastases in
orthotopic implantation model system showed higher expression activities than colon primaries. No „clone selection” effect was detected in liver
colonisation model (after intrasplenic implantation). C. CD44v3 and v6 gene expression activity of non-metastatic (implanted into adult) and
metastatic (implanted into newborn) primary human colon carcinoma xenograft tumours implanted subcutaneously (heterotopicaly) into scid
mice. Expression rates are normalized on beta-actin expression rates and non-metastatic v3/v6 expression rates. All three examined human
colorectal carcinoma cell types showed higher CD44v3 and CD44v6 expression activities in metastatic system (subcutaneously implanted colon
tumours in newborn mice, which developed distant metastases in each animal cases) than in non-metastatic (the same colon carcinomas
implanted into adult mice subcuticularly without any single case of distant metastasis formation).
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standard form of CD44 (CD44s), but not variant ones
(CD44v), while highly dysplastic colorectal adenomas,
primary and metastatic colorectal cancers express alarge variety of different-length CD44 isoforms, both on
mRNA and protein levels [14,31,44,77-79]. Some of
these new CD44 isoforms acquired during malignant
transformation contain v3 and v6 domain which add a
Figure 4 CD44v3 and CD44v6 expression activity in human xenograft CRC metastatic and liver colonisation system. A. CD44v3
and v6 gene expression activity of primary and metastatic human colon carcinoma xenograft tumours (HT29, HT25 and HCT116) implanted
orthotopically (colonic wall)into scid mice. The three genetically different human colorectal carcinoma lines showed three different behaviours
in terms of CD44v3 and v6 expression rate changes during metastatic process. The reason of it might be the baseline level of expression in
prmary tumours: relative expression rates (CD44v3 and v6 expression normalized on β-actin expression rates) of the three tumour types showed
1–1 order of magnitude differences. As we measure summated expression rates (average) of each tumour cells of the particular tumour mass,
differences in CD44 variant exon expression levels might be explined with differences of CD44v3/v6 high cell proportion of the tumour cell mass.
B. Model of metastatic clone selection in each three cell lines, schematic explanation of the differences in a consequent model.
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existing CD44s functions, as CD44v6 is a co-receptor of
the met protein, and CD44v3 is one of the most import-
ant presenters of heparin-binding growth factors, such
as HGF, the main ligand of Met [60,62]. One must also
consider that multiple variable regions might be present
in a single isoform, adding further functional abilities. It
is likely that the molecular interactions of CD44v3 are
different from those of CD44v2-v10 variant despite both
containing the v3 region, yet they will be ‘measured’ as
a single product when using CD44v3 primers/probes/
antibodies. Again, probes against any particular exons
/protein domains od CD44 will demonstrate a wide
range of CD44 isoforms, all of which share the same
particular exon/domain. Furthermore, most of our testsare performed on mixtures of different tumour tissue
elements: these assays work on a conglomerate of
tumour cells, stromal cells, their proteins or gene pro-
ducts. Results of these reactions will lways represent
some sort of average or summation. This might influ-
ence the qualitative expression pisture of distinct gene
products of a tumour sample, but certainl will affect
quantitative one. Considering this makes it easier to
understand the contradictions of the literature.
Our aim was to identify a roster of CD44 isoforms
expressed by colorectal cancer to see the extent of com-
plexity we need to face when examining ‘CD44’. We also
wanted to determine whether a potential “malignant”
colorectal adenocarcinoma-specific isoform parttern
exists. We then aimed to examine the stability of this
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qualitatively stable or new isoforms become dominant.
This was tested in our complex iso- and xenograft
experimental animal models. Reproducibility of v3 and
v6 changes described in the literature was also tested in
our experimental animal models. These models enabled
us to separately study steps of tumour progression as
well as the role of the tumour microenvironment.
First of all we attempted to identify the expressed iso-
forms from the qualitative CD44 ASP. We concluded
that although not all the possible isoforms are expressed
in reality, it is still rather technically impossible to iden-
tify the ones that do get expressed.All three attempts of
ours on completing the isoform roster were only par-
tially successful: (i) Our A – B primer overlapped the
whole CD44 variable region, still just a few “dominant”
isoforms could be identified as qualitative PCR products
with direct sequencing. Some other isoforms could me
identified according to the PCR product length, as well.
Further CD44 variants were added by four other PCRs
carried out with primer pairs designed onto particular
exons of interest (v3 and v6). (ii) Next-generation
sequencing theoretically should provide an allele-specific
list of all transcribed isoforms. Still we reached limita-
tions of the technique, but managed to identify more,
sofar unidentified isoforms. (iii) I our previous publica-
tion on similar experimental set-up on melanoma (data
under publication, Rásó-Barnett et al., paper accepted)
identification attempt of “each” expressed CD44 isoform
by cloning was reported to be fruitful, but again far from
complete. We feel that the result of CD44 splicing is far
richer than the sensitivity and effectivity of today’s tests.
However, we do not yt know if this complexity of CD44
ASP carries any special functional importance. For now,
we need to focus on functional characterization of dis-
tinct exons/domains of the complex molecule selectively.
Although the complete CD44 isoform list was not
achieved, we identified simplified colorectal adenocarcin-
oma specific CD44 alternative splice pattern (ASP) which
was qualitatively stable across samples from different
colorectal cancer cell lines in vitro, and subcutaneous,
intrasplenic and orthotopic implanted primary colorectal
tumours and their liver metastases/colonies.
Although we know that not all of the expressed iso-
forms can be detected this way, the overlapping primer
pairs we used covered the whole variable region, and
provided a simplified pattern (ASP) which could be eas-
ily used to follow the possible changes of CD44 spilicing
even in more complex in vivo systems. These results
proved that, unlike the appearance of new CD44
isoforms during tumorigenesis, no new CD44 isoforms
appear during tumour progression from primary
tumour to metastasis. Therefore, it was likely that the
expression changes of specific variant containing isoforms(as published in the literature) should be rather caused by
quantitative changes of a set of isoforms.
Hence, we focused on quantitative expression of two
particular exons: v3 and v6. These two exons also
appeared to be dominant on our reported qualitative
ASP pictures. We separately examined their role in dif-
ferent steps of metastatic cascade in our complex animal
experimental model system. Furthermore we managed
to gain a glimpse of the role of tumour microenviron-
ment (host) in the modulation of CD44 splice variant
expression in conjunction with metastatic potential,
as well.
Our isograft model (Balb/C – C26) proved that quan-
titative changes only happen during real metastasis for-
mation, considering that v3 and v6 expression levels of
both orthotopic and heterotopic implanted primary
tumours were similar, but increased expression levels
were only detected in real liver metastases and not in
the colonies. This means that the higher expression level
of v3 and v6 is not the effect of the liver microenviron-
ment, but it is the actual pre-existing feature of distinct
metastatic cells within the primary tumour. While at
orthotopic implantation into large bowel wall tumour
cells must undergo each classical steps of metastasis
formation (EMT, intravasation, survival in circulation,
extravasation, MET, proliferation in metastatic target
organ), intrasplenic implantation gives the chance to a
proportion of tumour cells to get straingt into the circula-
tion by skipping the early phases of the cascade. Compari-
son of the two models can potentially differenciate between
genes, gene products that act in different in different phases
of metastatic process.
The same theory was tested in a human xenograft
model as well. HT29 human colorectal adenocarcinoma
xenograft showed similar results to the C26 isograft,
while both HT25 and HCT116 behaved differently,
which proposed further explanation to the contradic-
tions of CD44 literature. We hypothesise that a higher
v3/v6 expression level is a necessary, but probably not
satisfactory prerequisite of cellular metastatic capability.
This is proven by the fact that real liver metastases of all
three CRC cell lines expressed v3 and v6 in the same
range, despite the different expression levels of their
colonic primaries Figure 4A,B. This also means, that the
number of cells expressing high levels of CD44v3 and v6
is not necessarily high within the primary tumour, as
theoretically a single ‘highly expressing’ clone is enough
for metastasis formation. In a similar experimental
model system circulating tumour cells of malignant mel-
anoma were found to express CD44v3 and v6 containing
varints on a high level in real metastatic system (Rásó-
Barnett et al. under publication) Correlating this with
our result would mean that HT29 had the lowest, while
HT25 and HCT116 had the higher percentage of ‘highly
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the possibility of a primary tumour showing relatively
higher expression levels than its metastasis, which would
have already been re-selected by the new microenviron-
ment. Translating this into clinical practice would mean,
that the ‘lack’ of overexpression would not exclude
metastatic potential or even a worse prognosis. As pri-
mary tumour site seemed to be interesting in terms of
selection of metastatically potent, CD44v3/v6 high sub-
clones, we tried to find support os this theory in another,
quite different model system.
We further examined the role of the primary tumour
microenvironment in our subcutaneously implanted
xenograft model. CD44v3 and v6 expression levels were
different in tumours implanted from the same cell sus-
pension, into genetically identical host, i.e. newborn and
adult scid mice, which were only physiologically differ-
ent. Hence, differences in expression levels of the exam-
ined gene products (v3 and v6) could be correlated with
differences in metastatic potential (0% vs. 100%). Micro-
environmental (host) factors (such as maturity immune
system, vascular permeability, cytokines and chemo-
kines, etc.) should, therefore, stand as driving factors in
the background of metastatically potent subclones which
will ultimately determine the clinical behaviour of the
entire tumour. These experiments prove that physio-
logical factors of host (as well as primary tumour micro-
environment) do matter and in extreme, experimental
conditions can fully determine metastatic potential of a
malignant system.
Conclusions
It is likely to assume that tumour microenvironment
(tumour host organism) have a central role in metastatic
phenotype presentation of primary colorectal cancer.
While normal tissues (such as colonic mucosa) do not
express variant isoforms of CD44, tumours seem to per-
form a wide variation of CD44 isoforms. Presuming that
different domains of different CD44 isoforms can perform
a variety of new functions, there is no more sense in
investigating CD44 “in general”.
Moreover, expression pattern of CD44 isoforms was
found to be stable, meaning that colorectal type expression
profile remained unchanged from tumour cell suspen-
sions (in vitro) throughout primary and metastatic colon
cancer xenografts. In contrary, quantitative changes do
exist in the expression of distinct variant exons.
CD44 variant isoforms, especially the functionally
well-characterized v3 and v6 containing isoforms, seem
to massively take part in expressing the metastatic
phenotype. Our results support that higher-level v3/v6
co-expression can represent this “quasy-metastatic-gene”
function at the primary tumour site and at the early
phase of the metastatic cascade. Nontheless, it must beemphasized that only a minor proportion of the primary
tumour mass is sufficient to hold “metastatic-phenotype”
for the complete primary tumour. Although each colo-
rectal tumour types use metastatic subclones of high
CD44v3/v6 expression rate, selective examination of
metastatic tumour cell group is not yet resolved. This
means that quantitative evaluation of not only CD44 “in
general”, but even of v3/v6-containing isoforms are
inappropriate for the prognosis of metastatic behavior
of a single tumour case because of the summative way
of the measurement techniques. Moreover this can be
the background of the quite diversive results on the pre-
dictive value of “CD44” in the literature.
Methods
Tumour cell cultures
We maintained cell cultures of three genetically different
human colorectal cell lines (HT25 (from M.Hendricks,
Iowa), HT29 (ECACC 91072201) and HCT116 (ICLC
HTL95025)), four other human neoplastic cell lines
(MCF7 – human breast cancer cell line (ATCC HTB-22™),
K562 – chronic myelogenous leukemia cell line (ATCC
CCL-243™), A431 – human vulvar epidermoid carcinoma
cell line (ATCC CRL 1555), HT199 – human malignant
melanoma cell line (developed in the 1st Department of
Pathology and Experimental Cancer Research (Semmel-
weis University, Budapest, Hungary)) and a mouse colo-
rectal cell line (C26 - derived from BALB/C Colon26
murine colon adenocarcinoma - obtained from ATCC.
USA) in 5% FCS and 1% Penicillin/Streptomycin con-
taining 1640-RPMI medium at 37°C. For implantation we
prepared single-cell suspensions after enzymatic (Tripsine-
EDTA) digestion and washed the cultures twice with FCS-
free medium.
In vivo experimental models
Isograft model
We injected suspensions of C26 isograft colorectal
tumour cell line into the spleen (4 animals) [80]and
colonic wall (4 animals) of adult (20-week-old, 20g –
weigh) Balb-C mice. Anaesthesia was performed by
intraperitoneal injection of Nembuthal (70 mg/kg). Each
tumour injection was performed by 0.05 ml suspension
of 5x105 cells (107 cell/ml serum-free one-cell suspen-
sions). After 4 weeks, animals were sacrificed, autopsy
was performed and tumour tissues of primary tumours
and liver metastases were isolated Figure 5I.a,I.b.
Human xenograft model I. - spontaneous lung metastatic
model from heterotopic (subcutaneous) implantation
Single cell suspension of HT25, HT29 and HCT116 cell
lines (5x105 cells / 0.05 ml) were subcutaneously
implanted into adult and newborn scid mice into the
same localization (left lumbar region) using the same
Figure 5 Complex animal model system. I. Liver metastasis (I.a) / colonisation (I.b) model. Human xenograft colon cancer cell suspensions
(HT29, HCT116 and HT25) were intracolonic and intrasplenic injected to scid mice; C26 mouse isograft colon cancer cell suspension was injected
into Balb/C mice. In proper „metastasis” system the whole metastatic sequence is represented, while „colonisation” model represents just the later
part of metastatic cascade. II. Spontaneous lung metastatsis model of subcutaneous (heterotopic) tumour injection: single cell suspension of
human xenograft colon cancer was injected into adult and newborn scid mice. Primary tumours were grown in both cases, while pulmonary
metastases were produced only in the newborn.
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were dissected from the sacrificed animals after 3 weeks
Figure 5II. This model provides particular chance to
examine “host” driven changes in the behavior of cancer
cell suspensions: while in newbrn mice pulmonary
metastases are being formed in each experimental
cases, the same cell suspensions are never becoming
“metastatic” after implantation into adult mice. The two
systems (permissive and non-permissive) were only
different in “host age”.
Micrometastases were verified on frozen sections of
the lung.
Human xenograft model II - Liver-metastasis models from
orthotopic and heterotopic implantation
We performed xenotransplantation of the already men-
tioned three human colorectal cancer cell lines (5x105
cells / 0.05 ml) into the spleen (heterotopic implantation)
and into the colonic wall (orthotopic implantation) of20-25g-weigh adult scid mice. The operations were per-
formed under intraperitoneal anaesthesia with 70 mg/kg
Nembutal. Animals were sacrificed after 8–10 weeks
when obvious signs of cachexia showed (more than
20% of weight loss of animal occurred). Primary and
metastatic tumours were dissected during autopsy
Figure 5I.a,I.b.
Samples from primary and metastatic tumours of
all three experimental animal models were processed
by freezing them immediately after removal for mole-
cular biology.
All animal experiments have been approved by the local
Animal Experimental Research Board (TUKEB83/2009).Total RNA isolation
Tumour tissue was fronzen in liqued nitrogen and
homogenized in mortar prior to RNA isolation. Total
RNA was isolated with TrizolW (SIGMA) according to
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ation was eliminated with TURBO DNA-free™ (Ambion).
Reverse transcription
For reverse transcription 1 μl of 10mM dNTP mix
(FinnzymeW) and 1μl of random nonamer-oligo dT com-
bination for a final concentration of 2.5 μM was added
to 2 μg of purified total RNA. After incubating at 70°C
for 10 min 2 μl of 10x M-MLV Reverse Transcriptase
Buffer (FinnzymeW), 1μl of M-MLV Reverse Transcriptase
(200 units/μl, FinnzymeW), 0.5 μl RNase Inhibitor
(40 units/μl, PromegaW) and 6.5 μl RNAse free water was
added for the final volume of 20 μl than incubated at 37°C
for 50 min and 85°C for 10 min.
For checking the occurance of reverse transcription, β-
actin was used as a housekeeping gene (βS1: 5’– TCT GGC
ACC ACA CCT TCT AC–3’ and βA4: 5’–CTC CTT AAT
GTC ACG CAC GAT TTC–3’, for murine tumours: MßS1
(RefSeq NM_007393):5’-AGA CAA CAT TGG CAT GGC
TT-3’, MßA1:5’-AAT GAA GTA TTA AGG CGG AAG
ATT-3’), respectively). Under the same PCR conditions,
RNA of the same sample was used as negative control for
detecting DNA contamination and DEPC treated, RNAse
free water as non-template control.
PCR analysis
For investigation of the variable regions of CD44, serial
PCR reactions were carried out with five different
human-specific primer pairs (A:Standard 5’ : AGT CAC
AGA CCT GCC CAA TGC CTT T, B:Standard 3’: TTT
GCT CCA CCT TCT TGA CTC CCA TG, C:v3 exon
5’: GGG AGC CAA ATG AAG AAA ATG AAG ATG
AAA G, D:v3 exon 3’ : GGT GCC TGT CTC TTT CAT
CTT CAT TTT CTT CAT TT, E:v6 exon 3’: TCT GTT
GCC AAA CCA CTG TTC CTT CTG) [22] Figure 2A.
The PCR reaction mixture contained 2.5 μl 10X PCR
buffer+Mg2+ (DyNazymeTM), 2 μl dNTP mix (2.5 mM
each), 0.4 μl DNA polymerase (DyNazymeTM, 2 U/μl),
2.5-2.5 μl of the primers, 2 μl of the cDNA and 13.1 μl
DEPC treated water for the final volume of 25 μl. The
cycling conditions were: 94°C for 12min once, then 94°C
for 1 min, 65°C for 1 min, 72°C for 1 min for 40 cycles
and the extension step was 72°C for 10 min.
PCR products were separated on a 3% agarose gel and
detected with Gel Doc 2000 (Bio-RadW) after ethidium
bromide staining.
Transcribed isoforms were identified by re-extraction,
and direct sequencing (Big Dye Terminator cycle
sequencing, Applied Biosystems 3130 Genetic Analyzer)
of the distinct bands.
Quantitative PCR analysis
For quantitative measurement of CD44v3 and v6 vari-
able exons q-PCR reactions were used. Each 25 μlreaction mixture contained 12.5 μl 2X iQ SYBRW Green
Supermix (Bio-Rad), 0.5-0.5 μl of each primer for final
concentration of 200nM and 11.5 μl of the diluted
cDNA. The cycling conditions comprised 3 min of iTaq™
DNA polymerase activation at 95°C, 40 cycles at 95°C
for 30 sec, 55°C for 30 sec, 72°C for 1 min. Starting
quantities were defined on the basis of standard five-fold
dilution series (x1-625) carried out with control cDNA
of A431 (human squamous cell carcinoma). Relative ex-
pression of the examined v3 (primers: CGT CTT CAA
ATA CCA TCT CAG CA and ATC TTC ATC ATC
AAT GCC TGA) and v6 (primers: GGC AAC TCC
TAG TAG TAC AAC G and GTC TTC TCT GGG
TGT TTG GC) variable exons were determined by
normalizing the starting quantities to the housekeeping
β-actin (primers: GTG GGG CGC CCC AGG CAC CA
and CTC CTT AAT GTC ACG CAC GAT TTC) start-
ing quantities from the same cDNA sample.
Next-generation, allele-specific sequencing
In order to prove identified CD44 isoforms specific to
colorectal cancer, next-generation sequencing method
was performed. The method briefly is as follows: PCR
reaction products from HT29, HT25 and HCT116
human colorectal cell lines (total RNA isolation, purifi-
cation, reverse transcription as mentioned above) with
primer pair A – B (primers designed on 5’ and 3’ standard
region of CD44 framing the entire variable region, hence
theoretically amplifying all the transcribed variant iso-
forms at the same time) were first amplified, purified with
High pure PCR clean-up micro kit (RocheW, Mannheim)
according to the manufacturer’s instructions. The ampli-
con ends were polished and ligated with roche 454
multiplex identifier (MID) adaptors, so that universal
primer binding sites were generated for emulsion PCR.
The amplicons were than separated with magnetic ampure
beads (Agencourt), non-bound adaptors were eliminated.
Emulsion PCR (emPCR) reaction was performed with
molarly equivalent amount of sample amplicons according
to the manufacturer’s protocol (Roche 454W) in modified
condition of low A,B primer concentration and slow PCR
program to minimalize the amplification efficiency differ-
ences between longer and shorter variants. CD44 variant
isoform library was clonally amplified with pyrosequencing
technique (454 GS Junior, RocheW), under the condition of
5% bead-ratio, 200 sequencing cycles, 400 bases read
length mode.
Amplicon variant analyzer software (Roche DiagnosticsW)
was used to eliminate multiplicity of the samples after
MIDs, to trim the primers and to align the reads to the
reference cDNA sequence. For easier handling of the huge
database of sequenced isoforms of the critically long CD44
molecule, exon-by-exon fishing technique was adapted to
identify each amplified exon-combination splice variants.
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threshold of matching rate of 90%. The exon combinations
which have more than 50 reads were reported.
Similar process was performed by the four other primer
combinations (Primer A-D, A-E, C-B and C-E, respectively.
See Figure 2A and Methods above).
Statistical analysis
Real-time PCR results, relative expression rates (normalized
on beta-actin expression rates) were compared with two-
sample T-tests (data were showing normal distribution).
Statistical significance was assumed at p< 0.05.
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